Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations
TL;DR
CDK4/6i selection should therefore be individualized according to toxicity profile, comorbidities, monitoring feasibility, and patient preference, with cautious interpretation of indirect comparative and real-world evidence.
Abstract
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are a standard treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer, but differences in toxicity, monitoring requirements, and dose-modification patterns influence clinical use. This integrative narrative review compares the safety, tolerability, dose-modification strategies, and clinical applicability of palbociclib, ribociclib, and abemaciclib. PubMed/MEDLINE, Embase, and Scopus were searched for English-language publications from January 2007 to July 2025, alongside clinical trial registries, major oncology conference proceedings, real-world studies, and American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and NCCN guidance documents. Evidence from pivotal phase II/III trials, real-world cohorts, and guideline-based recommendations was synthesized qualitatively. All three agents consistently improved progression-free survival, confirming cyclin-dependent kinase 4 and 6 (CDK4/6) inhibition as a class effect. Ribociclib appeared to show the most consistent overall survival benefit across phase III trials, although no head-to-head comparisons exist, and indirect cross-trial interpretation requires caution. Palbociclib showed predictable hematologic toxicity with established dose-adjustment algorithms. Ribociclib required additional hepatic and electrocardiographic monitoring due to the risk of hepatotoxicity and QT prolongation. Abemaciclib allowed continuous dosing with less severe neutropenia but higher rates of diarrhea and venous thromboembolism. Real-world evidence supported dose reduction and interruption as effective safety-management strategies without clear loss of benefit, although observational data remained heterogeneous and subject to bias. CDK4/6i selection should therefore be individualized according to toxicity profile, comorbidities, monitoring feasibility, and patient preference, with cautious interpretation of indirect comparative and real-world evidence.